Aromatase inhibitors in advanced breast cancer

This publication has 31 references indexed in Scilit:

• First results of a randomized phase III trial comparing exemestane versus tamoxifen as first-line hormone therapy (HT) for postmenopausal women with metastatic breast cancer (MBC) — EORTC 10951 in collaboration with the exemestane working group and NCIC Clinical Trials Group
  European Journal of Cancer Supplements, 2004
• Challenges in the endocrine management of breast cancer
  The Breast, 2003
• Phase III Study of Letrozole Versus Tamoxifen as First-Line Therapy of Advanced Breast Cancer in Postmenopausal Women: Analysis of Survival and Update of Efficacy From the International Letrozole Breast Cancer Group
  Journal of Clinical Oncology, 2003
• Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma
  Cancer, 2001
• Superior Efficacy of Letrozole Versus Tamoxifen as First-Line Therapy for Postmenopausal Women With Advanced Breast Cancer: Results of a Phase III Study of the International Letrozole Breast Cancer Group
  Journal of Clinical Oncology, 2001
• Use of aromatase inhibitors in breast carcinoma.
  Endocrine-Related Cancer, 1999
• Hormonal treatment for metastatic breast cancer. An eastern cooperative oncology group phase III trial comparing aminoglutethimide to tamoxifen
  Cancer, 1994
• Primary endocrine therapy for advanced breast cancer: To start with tamoxifen or with medroxyprogesterone acetate?
  Annals of Oncology, 1993
• Endocrine Treatment of Breast Cancer in Women
  Endocrine Reviews, 1990
• Tamoxifen in the Treatment of Breast Cancer
  Annals of Internal Medicine, 1988